Squamous carcinoma cells influence monocyte phenotype and suppress lipopolysaccharide-induced tnf-alpha in monocytes

Inflammation

Volumn 33, Issue 4, 2010, Pages 207-223

  Lam ubol, Aroonwan ^a,b   Hopkin, Dustin ^c   Letuchy, Elena M ^d   Kurago, Zoya B ^a  

^a NEW YORK UNIVERSITY COLLEGE OF DENTISTRY   (United States)

^b SRINAKHARINWIROT UNIVERSITY   (Thailand)

^c INDIANA UNIVERSITY   (United States)

^d UNIVERSITY OF IOWA   (United States)

Author keywords

Carcinoma; Inflammation; Lipopolysaccharide; Monocytes; TNF alpha; Tumor microenvironment

Indexed keywords

CD16 ANTIGEN; CD56 ANTIGEN; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; TUMOR NECROSIS FACTOR ALPHA; FC RECEPTOR; FCGR3B PROTEIN, HUMAN; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; IL6 PROTEIN, HUMAN; LIPOPOLYSACCHARIDE, E. COLI 026-B6;

ANTIGEN EXPRESSION; ARTICLE; CANCER CELL; CELL DIFFERENTIATION; CELL PROTECTION; CELL SURVIVAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; HEAD AND NECK CARCINOMA; HUMAN; HUMAN CELL; KERATINOCYTE; MONOCYTE; MOUTH CARCINOMA; PATHOGENESIS; PHENOTYPE; REGULATORY MECHANISM; SQUAMOUS CELL CARCINOMA; TUMOR MICROENVIRONMENT; UPREGULATION; BIOSYNTHESIS; CELL CULTURE; COCULTURE; CYTOLOGY; DISEASE COURSE; DRUG EFFECTS; HEAD AND NECK TUMOR; IMMUNOLOGY; INFLAMMATION; MOUTH MUCOSA; PATHOLOGY; PHAGOCYTOSIS; SECRETION (PROCESS); STOMATITIS; TUMOR CELL LINE;

CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELLS, CULTURED; COCULTURE TECHNIQUES; DISEASE PROGRESSION; HEAD AND NECK NEOPLASMS; HUMANS; INFLAMMATION; INTERLEUKIN-6; KERATINOCYTES; LIPOPOLYSACCHARIDES; MONOCYTES; MOUTH MUCOSA; PHAGOCYTOSIS; PHENOTYPE; RECEPTORS, IGG; STOMATITIS; TUMOR NECROSIS FACTOR-ALPHA; GPI-LINKED PROTEINS;

EID: 77956187379     PISSN: 03603997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10753-009-9175-6     Document Type: Article

References (74)

1. Gallo, O., A.M. Gori, M. Attanasio, F. Martini, B. Giusti, T. Brunelli, et al. 1995. Interleukin-6 and acute-phase proteins in head and neck cancer. European Archives of Oto-Rhino-Laryngology 252: 159-162.
2. Druzgal, C.H., Z. Chen, N.T. Yeh, G.R. Thomas, F.G. Ondrey, D. C. Duffey, et al. 2005. A pilot study of longitudinal serum cytokine and angiogenesis factor levels as markers of therapeutic response and survival in patients with head and neck squamous cell carcinoma. Head and Neck 27: 771-784.
3. Chen, Z., P.S. Malhotra, G.R. Thomas, F.G. Ondrey, D.C. Duffey, C.W. Smith, et al. 1999. Expression of proinflammatory and proangiogenic cytokines in patients with head and neck cancer. Clinical Cancer Research 5: 1369-1379.
4. Sparano, A., D.M. Lathers, N. Achille, G.J. Petruzzelli, and M.R. Young. 2004. Modulation of Th1 and Th2 cytokine profiles and their association with advanced head and neck squamous cell carcinoma. Otolaryngology - Head and Neck Surgery 131: 573-576.
5. Yin, W., S. Cheepala, J.N. Roberts, K. Syson-Chan, J. DiGiovanni, and J.L. Clifford. 2006. Active Stat3 is required for survival of human squamous cell carcinoma cells in serum-free conditions. Molecular Cancer 5: 15.
6. Buettner, R., L.B. Mora, and R. Jove. 2002. Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clinical Cancer Research 8: 945-954.
7. Hirano, T., K. Ishihara, and M. Hibi. 2000. Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors. Oncogene 19: 2548-2556.
8. Squarize, C.H., R.M. Castilho, V. Sriuranpong, D.S. Pinto Jr., and J.S. Gutkind. 2006. Molecular cross-talk between the NFkappaB and STAT3 signaling pathways in head and neck squamous cell carcinoma. Neoplasia 8: 733-746.
9. Sriuranpong, V., J.I. Park, P. Amornphimoltham, V. Patel, B.D. Nelkin, and J.S. Gutkind. 2003. Epidermal growth factor receptorindependent constitutive activation of STAT3 in head and neck squamous cell carcinoma is mediated by the autocrine/paracrine stimulation of the interleukin 6/gp130 cytokine system. Cancer Research 63: 2948-2956.
10. Hodge, D.R., E.M. Hurt, and W.L. Farrar. 2005. The role of IL-6 and STAT3 in inflammation and cancer. European Journal of Cancer 41: 2502-2512.
11. Grandis, J.R., S.D. Drenning, Q. Zeng, S.C. Watkins, M.F. Melhem, S. Endo, et al. 2000. Constitutive activation of Stat3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo. Proceedings of the National Academy of Sciences of the United States of America 97: 4227-4232.
12. Woods, K.V., A. El-Naggar, G.L. Clayman, and E.A. Grimm.1998. Variable expression of cytokines in human head and neck squamous cell carcinoma cell lines and consistent expression in surgical specimens. Cancer Research 58: 3132-3141.
13. Kurago, Z.B., A. Lamubol, A. Stetsenko, C. De La Mater, Y. Chen, and D.V. Dawson. 2008. Lipopolysaccharide-squamous cell carcinoma- monocyte interactions induce cancer-supporting factors leading to rapid STAT3 activation. Head and Neck Pathology 2: 1-12.
14. Ohta, M., Y. Kitadai, S. Tanaka, M. Yoshihara, W. Yasui, N. Mukaida, et al. 2002. Monocyte chemoattractant protein-1 expression correlates with macrophage infiltration and tumor vascularity in human esophageal squamous cell carcinomas. International Journal of Cancer 102: 220-224.
15. Koide, N., A. Nishio, T. Sato, A. Sugiyama, and S. Miyagawa. 2004. Significance of macrophage chemoattractant protein-1 expression and macrophage infiltration in squamous cell carcinoma of the esophagus. American Journal of Gastroenterology 99: 1667-1674.
16. Li, C., S. Shintani, N. Terakado, K. Nakashiro, and H. Hamakawa.2002. Infiltration of tumor-associated macrophages in human oral squamous cell carcinoma. Oncology Reports 9: 1219-1223.
17. Marcus, B., D. Arenberg, J. Lee, C. Kleer, D.B. Chepeha, C.E. Schmalbach, et al. 2004. Prognostic factors in oral cavity and oropharyngeal squamous cell carcinoma. Cancer 101: 2779-2787.
18. Sakamoto, H., J. Sasaki, and C.E. Nord. 1999. Association between bacterial colonization on the tumor, bacterial translocation to the cervical lymph nodes and subsequent postoperative infection in patients with oral cancer. Clinical Microbiology & Infection 5: 612-616.
19. Hooper, S.J., S.J. Crean, M.A. Lewis, D.A. Spratt, W.G. Wade, and M.J. Wilson. 2006. Viable bacteria present within oral squamous cell carcinoma tissue. Journal of Clinical Microbiology 44: 1719-1725.
20. Hooper, S.J., S.J. Crean, M.J. Fardy, M.A. Lewis, D.A. Spratt, W. G. Wade, et al. 2007. A molecular analysis of the bacteria present within oral squamous cell carcinoma. Journal of Medical Microbiology 56: 1651-1659.
21. Sakamoto, H., H. Naito, Y. Ohta, R. Tanakna, N. Maeda, J. Sasaki, et al. 1999. Isolation of bacteria from cervical lymph nodes in patients with oral cancer. Archives of Oral Biology 44: 789-793.
22. Kelly, M.G., A.B. Alvero, R. Chen, D.A. Silasi, V.M. Abrahams, S. Chan, et al. 2006. TLR-4 signaling promotes tumor growth and paclitaxel chemoresistance in ovarian cancer. Cancer Research 66: 3859-3868.
23. Fukata, M., and M.T. Abreu. 2008. Role of Toll-like receptors in gastrointestinal malignancies. Oncogene 27: 234-243.
24. Kundu, S.D., C. Lee, B.K. Billips, G.M. Habermacher, Q. Zhang, V. Liu, et al. 2008. The toll-like receptor pathway: A novel mechanism of infection-induced carcinogenesis of prostate epithelial cells. The Prostate 68: 223-229.
25. Santiago, C., B. Pagan, A.A. Isidro, and C.B. Appleyard. 2007. Prolonged chronic inflammation progresses to dysplasia in a novel rat model of colitis-associated colon cancer. Cancer Research 67: 10766-10773.
26. Huang, B., J. Zhao, S. Shen, H. Li, K.L. He, G.X. Shen, et al.2007. Listeria monocytogenes promotes tumor growth via tumor cell toll-like receptor 2 signaling. Cancer Research 67: 4346-4352.
27. van der Bruggen, T., S. Nijenhuis, E. van Raaij, J. Verhoef, and B. S. van Asbeck. 1999. Lipopolysaccharide-induced tumor necrosis factor alpha production by human monocytes involves the raf-1/ MEK1-MEK2/ERK1-ERK2 pathway. Infection and Immunity 67: 3824-3829.
28. Balkwill, F.R., A. Lee, G. Aldam, E. Moodie, J.A. Thomas, J. Tavernier, et al. 1986. Human tumor xenografts treated with recombinant human tumor necrosis factor alone or in combination with interferons. Cancer Research 46: 3990-3993.
29. Strangfeld, A., and J. Listing. 2006. Infection and musculoskeletal conditions: Bacterial and opportunistic infections during anti-TNF therapy. Best Practice & Research Clinical Rheumatology 20: 1181-1195.
30. Larrick, J.W., and S.C. Wright. 1990. Cytotoxic mechanism of tumor necrosis factor-alpha. Faseb Journal 4: 3215-3223.
31. Sacchi, M., I. Klapan, J.T. Johnson, and T.L. Whiteside. 1991. Antiproliferative effects of cytokines on squamous cell carcinoma. Archives of Otolaryngology - Head and Neck Surgery 117: 321-326.
32. Kim, K.D., J. Zhao, S. Auh, X. Yang, P. Du, H. Tang, et al. 2007. Adaptive immune cells temper initial innate responses. Nature Medicine 13: 1248-1252.
33. Okamoto, H., K. Mizuno, and T. Horio. 2003. Circulating CD14+ CD16+ monocytes are expanded in sarcoidosis patients. Journal of Dermatology 30: 503-509.
34. Kawanaka, N., M. Yamamura, T. Aita, Y. Morita, A. Okamoto, M. Kawashima, et al. 2002. CD14+, CD16+ blood monocytes and joint inflammation in rheumatoid arthritis. Arthritis and Rheumatism 46: 2578-2586.
35. Soares, G., A. Barral, J.M. Costa, M. Barral-Netto, and J. Van Weyenbergh. 2006. CD16+ monocytes in human cutaneous leishmaniasis: Increased ex vivo levels and correlation with clinical data. Journal of Leukocyte Biology 79: 36-39.
36. Ziegler-Heitbrock, L. 2007. The CD14+ CD16+ blood monocytes: Their role in infection and inflammation. Journal of Leukocyte Biology 81: 584-592.
37. Grip, O., A. Bredberg, S. Lindgren, and G. Henriksson. 2007. Increased subpopulations of CD16(+) and CD56(+) blood monocytes in patients with active Crohn's disease. Inflammatory Bowel Diseases 13: 566-572.
38. Saleh, M.N., S.J. Goldman, A.F. LoBuglio, A.C. Beall, H. Sabio, M.C. McCord, et al. 1995. CD16+ monocytes in patients with cancer: Spontaneous elevation and pharmacologic induction by recombinant human macrophage colony-stimulating factor. Blood 85: 2910-2917.
39. Randolph, G.J., G. Sanchez-Schmitz, R.M. Liebman, and K. Schakel. 2002. The CD16(+) (FcgammaRIII(+)) subset of human monocytes preferentially becomes migratory dendritic cells in a model tissue setting. Journal of Experimental Medicine 196: 517-527.
40. Varol, C., L. Landsman, D.K. Fogg, L. Greenshtein, B. Gildor, R. Margalit, et al. 2007. Monocytes give rise to mucosal, but not splenic, conventional dendritic cells. Journal of Experimental Medicine 204: 171-180.
41. Tanaka, M., J. Honda, Y. Imamura, K. Shiraishi, K. Tanaka, and K. Oizumi. 1999. Surface phenotype analysis of CD16+ monocytes from leukapheresis collections for peripheral blood progenitors. Clinical and Experimental Immunology 116: 57-61.
42. Ancuta, P., L. Weiss, and N. Haeffner-Cavaillon. 2000. CD14 +CD16++ cells derived in vitro from peripheral blood monocytes exhibit phenotypic and functional dendritic cell-like characteristics. European Journal of Immunology 30: 1872-1883.
43. Logullo, A.F., S. Nonogaki, R.E. Miguel, L.P. Kowalski, I.N. Nishimoto, F.S. Pasini, et al. 2003. Transforming growth factor beta1 (TGFbeta1) expression in head and neck squamous cell carcinoma patients as related to prognosis. Journal of Oral Pathology & Medicine 32: 139-145.
44. Marsh, C.B., M.D. Wewers, L.C. Tan, and B.H. Rovin. 1997. Fc (gamma) receptor cross-linking induces peripheral blood mononuclear cell monocyte chemoattractant protein-1 expression: Role of lymphocyte Fc(gamma)RIII. Journal of Immunology 158: 1078-1084.
45. Wang, Z.Q., A.S. Bapat, R.J. Rayanade, A.S. Dagtas, and M.K. Hoffmann. 2001. Interleukin-10 induces macrophage apoptosis and expression of CD16 (FcgammaRIII) whose engagement blocks the cell death programme and facilitates differentiation. Immunology 102: 331-337.
46. Polumuri, S.K., V.Y. Toshchakov, and S.N. Vogel. 2007. Role of phosphatidylinositol-3 kinase in transcriptional regulation of TLRinduced IL-12 and IL-10 by Fc gamma receptor ligation in murine macrophages. Journal of Immunology 179: 236-246.
47. Song, J.I., and J.R. Grandis. 2000. STAT signaling in head and neck cancer. Oncogene 19: 2489-2495.
48. Lucey, D.R., M. Clerici, and G.M. Shearer. 1996. Type 1 and type 2 cytokine dysregulation in human infectious, neoplastic, and inflammatory diseases. Clinical Microbiology Reviews 9: 532-562.
49. Diehl, S., and M. Rincon. 2002. The two faces of IL-6 on Th1/Th2 differentiation. Molecular Immunology 39: 531-536.
50. O'Farrell, A.M., Y. Liu, K.W. Moore, and A.L. Mui. 1998. IL-10 inhibits macrophage activation and proliferation by distinct signaling mechanisms: Evidence for Stat3-dependent and -independent pathways. Embo Journal 17: 1006-1018.
51. Cheng, F., H.W. Wang, A. Cuenca, M. Huang, T. Ghansah, J. Brayer, et al. 2003. A critical role for Stat3 signaling in immune tolerance. Immunity 19: 425-436.
52. Williams, L., L. Bradley, A. Smith, and B. Foxwell. 2004. Signal transducer and activator of transcription 3 is the dominant mediator of the anti-inflammatory effects of IL-10 in human macrophages. Journal of Immunology 172: 567-576.
53. Murray, P.J. 2006. Understanding and exploiting the endogenous interleukin-10/STAT3-mediated anti-inflammatory response. Current Opinion in Pharmacology 6: 379-386.
54. Nishiki, S., F. Hato, N. Kamata, E. Sakamoto, T. Hasegawa, A. Kimura-Eto, et al. 2004. Selective activation of STAT3 in human monocytes stimulated by G-CSF: Implication in inhibition of LPSinduced TNF-alpha production. American Journal of Physiology. Cell Physiology 286: C1302-C1311.
55. del Fresno, C., K. Otero, L. Gomez-Garcia, M.C. Gonzalez-Leon, L. Soler-Ranger, P. Fuentes-Prior, et al. 2005. Tumor cells deactivate human monocytes by up-regulating IL-1 receptor associated kinase-M expression via CD44 and TLR4. Journal of Immunology 174: 3032-3040.
56. Mytar, B., M. Woloszyn, R. Szatanek, M. Baj-Krzyworzeka, M. Siedlar, I. Ruggiero, et al. 2003. Tumor cell-induced deactivation of human monocytes. Journal of Leukocyte Biology 74: 1094-1101.
57. Franzmann, E.J., G.L. Schroeder, W.J. Goodwin, D.T. Weed, P. Fisher, and V.B. Lokeshwar. 2003. Expression of tumor markers hyaluronic acid and hyaluronidase (HYAL1) in head and neck tumors. International Journal of Cancer 106: 438-445.
58. Yasuda, T. 2007. Hyaluronan inhibits cytokine production by lipopolysaccharide-stimulated U937 macrophages through downregulation of NF-kappaB via ICAM-1. Inflammation Research 56: 246-253.
59. Bose, A., T. Chakraborty, K. Chakraborty, S. Pal, and R. Baral. 2008. Dysregulation in immune functions is reflected in tumor cell cytotoxicity by peripheral blood mononuclear cells from head and neck squamous cell carcinoma patients. Cancer Immunity 8: 10.
60. Lopez-Gonzalez, J.S., F. Avila-Moreno, H. Prado-Garcia, D. Aguilar- Cazares, J.J. Mandoki, and M. Meneses-Flores. 2007. Lung carcinomas decrease the number of monocytes/macrophages (CD14+ cells) that produce TNF-alpha. Clinical Immunology 122: 323-329.
61. Briskin, K.B., C. Fady, M. Wang, and A. Lichtenstein. 1996. Apoptotic inhibition of head and neck squamous cell carcinoma cells by tumor necrosis factor alpha. Archives of Otolaryngology - Head and Neck Surgery 122: 559-563.
62. Mochimatsu, I., M. Tsukuda, S. Furukawa, S. Watanabe, A. Kubota, and S. Yanoma. 1993. The sensitivity of head and neck squamous cell carcinomas to tumor necrosis factor-alpha. Biotherapy 6: 239-244.
63. Balkwill, F. 2002. Tumor necrosis factor or tumor promoting factor? Cytokine and Growth Factor Reviews 13: 135-141.
64. Fajardo, L.F., H.H. Kwan, J. Kowalski, S.D. Prionas, and A.C. Allison. 1992. Dual role of tumor necrosis factor-alpha in angiogenesis. American Journal of Pathology 140: 539-544.
65. Wu, S., C.M. Boyer, R.S. Whitaker, A. Berchuck, J.R. Wiener, J.B. Weinberg, et al. 1993. Tumor necrosis factor alpha as an autocrine and paracrine growth factor for ovarian cancer: Monokine induction of tumor cell proliferation and tumor necrosis factor alpha expression. Cancer Research 53: 1939-1944.
66. Lejeune, F.J. 2002. Clinical use of TNF revisited: Improving penetration of anti-cancer agents by increasing vascular permeability. Journal of Clinical Investigation 110: 433-435.
67. Iwamoto, S., S. Iwai, K. Tsujiyama, C. Kurahashi, K. Takeshita, M. Naoe, et al. 2007. TNF-alpha drives human CD14+ monocytes to differentiate into CD70+ dendritic cells evoking Th1 and Th17 responses. Journal of Immunology 179: 1449-1457.
68. Ganz, T. 2003. Defensins: Antimicrobial peptides of innate immunity. Nature Reviews. Immunology 3: 710-720.
69. Joly, S., C. Maze, P.B. McCray Jr., and J.M. Guthmiller. 2004. Human beta-defensins 2 and 3 demonstrate strain-selective activity against oral microorganisms. Journal of Clinical Microbiology 42: 1024-1029.
70. Singer, A.J., and R.A. Clark. 1999. Cutaneous wound healing. New England Journal of Medicine 341: 738-746.
71. Leibovich, S.J., and R. Ross. 1975. role of the macrophage in wound repair. A study with hydrocortisone and antimacrophage serum. American Journal of Pathology 78: 71-100.
72. Pedersen, T.X., C. Leethanakul, V. Patel, D. Mitola, L.R. Lund, K. Dano, et al. 2003. Laser capture microdissection-based in vivo genomic profiling of wound keratinocytes identifies similarities and differences to squamous cell carcinoma. Oncogene 22: 3964-3976.
73. Sano, S., K.S. Chan, and J. DiGiovanni. 2008. Impact of Stat3 activation upon skin biology: A dichotomy of its role between homeostasis and diseases. Journal of Dermatological Science 50: 1-14.
74. Moore, M.B., Z.B. Kurago, C.A. Fullenkamp, and C.T. Lutz. 2003. Squamous cell carcinoma cells differentially stimulate NK cell effector functions: The role of IL-18. Cancer Immunology, Immunotherapy 52: 107-115.